Nanopharmaceutical Drugs Industry

1. GLOBAL NANOPHARMACEUTICAL DRUGS MARKET: FOCUS ON NANODRUGS AND ITS APPLICATION IN THERAPEUTICS, COMPETITIVE LANDSCAPE, AND COUNTRY - ANALYSIS AND FORECAST (2018-2026) Key Questions Answered in the Report: • What are the key features of the nanopharmaceutical drugs promoting its incorporation in different clinical applications? MORE THAN 40 COMPANIES RESEARCHED ACROSS THE VALUE CHAIN • What are key advantages of the nanopharmaceutical drug over conventional drug? • What shall be the business strategies and scope in the future? • What are the major market drivers, challenges, and opportunities in the global nanopharmaceutical drug market? • What are the key developmental strategies which are implemented by the key players to stand out in this market? • What are the leading companies dominating the global nanopharmaceutical drugs market? METICULOUS COMPILATION OF MORE THAN 700 RESEARCH HOURS • Which therapeutic application market would witness massive incorporation of the nanopharmaceutical drugs in the forecast period? • What are different types of drug carriers used in nanotechnology drug delivery systems? • What are the factors impacting the nanopharmaceutical market? • What are the key companies which made substantial investments to aid technological advancements in the market? EXCLUSIVE INSIGHTS FROM IN-DEPTH EXPERT INTERVIEWS • What are the regulations pertaining to the global nanopharmaceutical drugs market? • What are initiatives implemented by different government bodies for the growth of global nanopharmaceutical drugs market? • What is the market value of the leading segments and sub-segments of the global nanopharmaceutical drugs market? • How will each segment of the global nanopharmaceutical drugs market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2028? CONTAINS 22 MARKET DATA TABLES AND 194 FIGURES SPREAD ACROSS 267 PAGES • How will the industry evolve during the forecast period 2018-2028? • Which region will contribute to the highest sales of the global nanopharmaceutical drugs market during the forecast period? 1 www.bisresearch.com  sales@bisresearch.com

2. TABLE OF CONTENTS • What are Nanopharmaceuticals? • Historical Trends • Comparative Analysis of Conventional Medicine and Nanomedicine • Issues and Concerns in Nanotech Product Development and its Commercialization • Impact of Market Drivers and Market Restraints • Assumptions and Limitations for Market Size Calculations • Global Nanopharmaceutical Drugs Market Scenario RESEARCH SCOPE & METHODOLOGY • Report Scope • Global Nanopharmaceutical Drugs Market: Research Methodology • Impact Analysis • Market Drivers • Market Restraints • Market Opportunities • Market Trends MARKET OVERVIEW • Pipeline Analysis and Market Opportunity • Product Launches and Approvals MARKET DYNAMICS • Introduction • Patent Analysis • Funding Scenario • Regulatory Bodies COMPETITIVE INSIGHTS • Liposomes • Polymer • Nanocrystals • Inorganic • Protein • Others INDUSTRY INSIGHTS • Oncology • Neurology • Anti-inflammatory/Immunology • Anti-infective • Cardiovascular/Physiology • Others GLOBAL NANOPHARMACEUTICAL DRUG MARKET (BY DRUG CARRIER) GLOBAL NANOPHARMACEUTICAL DRUGS MARKET (BY APPLICATION) • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies GLOBAL NANOPHARMACEUTICAL DRUGS MARKET (BY DISTRIBUTION CHANNEL) • North America • Europe • Asia-Pacific • Rest-of-the-World GLOBAL NANOPHARMACEUTICAL DRUGS MARKET (BY REGION) • AbbVie Inc. • AMAG Pharmaceuticals • Amgen Inc. • Astellas Pharma Inc. • AstraZeneca PLC • CELGENE CORPORATION • Sanofi S.A • Gilead Sciences, Inc. • JOHNSON & JOHNSON • Merck & Co., Inc. • Novartis AG • Pfizer Inc. • Hoffmann-La Roche AG • Sanofi S.A • Shire Plc. • Teva Pharmaceuticals Industries Limited COMPANY PROFILES VIEW COMPLETE TABLE OF CONTENTS 2 www.bisresearch.com  sales@bisresearch.com

3. LIST OF TABLES 14 15 16 List of Inorganic NPs List of Protein NPs Currently Approved Nanomedicines in the Clinic (Cancer) North America Nanopharmaceutical Drugs Market (by Drug Carrier Type), 2017-2026, $Billion North America Nanopharmaceutical Drugs Market (by Application), 2017-2026, $Billion Europe Nanopharmaceutical Drugs Market (by Drug Carrier Type), 2017-2026 Europe Nanopharmaceutical Drugs Market (by Application), 2017-2026 Asia-Pacific Nanopharmaceutical Drugs Market(by Drug Carrier Type), 2017-2026 Asia-Pacific Nanopharmaceutical Drugs Market, by Application, 2017-2026 1 2 Cancer Incidences (by Region), 2015 Characterization Tools and Methods for Nanoparticles Various Characteristics and Brief Applications of Nanosystems Conventional Medicine vs. Nanomedicine Impact Analysis Drug Candidates in Different Phase of Development Nanopharmaceutical Drug Approvals Criterion for Patentability Selected Case Law Pertaining to Nanotechnology List of Regulatory Bodies across the World List of Liposome NPs List of Polymer NPs List of Nanocrystal NPs 3 17 4 5 6 18 19 7 8 9 10 11 12 13 20 21 22 LIST OF FIGURES 1 2 Evolution of Nanomedicine Global Nanopharmaceutical Drugs Market Share (by Drug Carrier Type), 2017 Global Nanopharmaceutical Drugs Market (by Drug Carrier Type), 2018 - 2026 Global Nanopharmaceutical Drugs Market (by Application), 2018 - 2026 Global Nanopharmaceutical Drugs Market (by Distribution Channel), 2018 - 2026 Global Nanopharmaceutical Drug Market, (by Region), 2017, 2021, and 2026 Global Nanopharmaceutical Drugs Market, 2017- 2026 Global Nanopharmaceutical Drugs Market, 2017- 2026, Y-o-Y Nanomedicine Market: Impacting Factors Global Nanopharmaceutical Drugs Market, Absolute Dollar Opportunity, Billion (by Region) Global Nanopharmaceutical Drugs Market, Market Attractiveness (By Application) Different Types of Biomarkers in Nanopharmaceutical Drug Drug Particle Prepared in the Nanoscale Depends on Four Aspects of Nanopharmaceutical Lifestyle Era of Nanodrug Delivery in Cancer Introduction to Nanomedicine: Years of Commercialization Concerns in Nanotech Product Development and its Commercialization Impact of Market Drivers and Market Restraints Global Nanopharmaceutical Drugs Market, 2017- 2026 Market Dynamics NNI Budget (by Agency), 2017–2019 (Proposed) Number of ANDA Approvals, 2017 Nanotechnology Business Pipeline Drugs: Clinical Opportunity Pipeline Drugs: On Map Nano based Drug Delivery Patent Filing, (By Region), 2015 Nanoparticles in Approved and Investigational Drugs, 2017 Market Potential, Drug Peak Sale ($Billion) Industry Insights Patent Expiration (By Drug Carrier Type), 2016 Types of Nanocarriers Global Nanopharmaceutical Drugs Market (by Drug Carrier Type), 2017 and 2026 Global Nanopharmaceutical Drugs Market (by Liposome Drug Carrier), 2017-2026 16 3 17 18 4 19 20 21 22 23 24 25 5 6 7 8 9 10 26 27 28 29 30 31 11 12 13 32 14 15 5 www.bisresearch.com  sales@bisresearch.com

4. LIST OF FIGURES 33 Global Nanopharmaceutical Drugs Market (by Polymer NP), 2017-2026 Global Nanopharmaceutical Drugs Market (by Nanocrystal Drug Carrier), 2017-2026 Global Nanopharmaceutical Drugs Market (by Inorganic), 2017-2026 Global Nanopharmaceutical Drugs Market (by Protein Drug Carrier), 2017-2026 Global Nanopharmaceutical Drugs Market (by Other Drug Carrier), 2017-2026 Global Nanopharmaceutical Drugs Market (by Application) Global Nanopharmaceutical Drugs Market (by Products), 2017-2026 Global Nanopharmaceutical Drugs Market (by Oncology), 2017-2026 Nanomedicine in Neurology Global Nanopharmaceutical Drugs Market (by Neurology), 2017-2026 Global Nanopharmaceutical Drugs Market (by Anti-inflammatory/Immunology), 2017-2026 Global Nanopharmaceutical Drugs Market (by Anti-infectives), 2017-2026 Global Nanopharmaceutical Drugs Market (by Cardiovascular and Physiology), 2017-2026 Global Nanopharmaceutical Drugs Market (by Other Application Areas), 2017-2026 Global Nanopharmaceutical Drugs Market (by Distribution Channel), 2017-2026 Global Nanopharmaceutical Drugs Market (by Hospital Pharmacy), 2017-2026 Global Nanopharmaceutical Drugs Market (by Retail and Drug Store), 2017-2026 Global Nanopharmaceutical Drugs Market (by Online Pharmacy), 2017-2026 Global Nanopharmaceutical Drugs Market Scenario, (CAGR), 2018-2026, (Market Value), (2017) Global Nanopharmaceutical Drugs Market (by Region), 2017-2026 Global Nanopharmaceutical Drugs Market Share (by Region), 2017 and 2026 North America Nanopharmaceutical Drugs Market, (2017-2026) North America Market Dynamics North America Nanopharmaceutical Drugs Market (by Country), 2017-2026 The U.S Nanopharmaceutical Drugs Market, 2017-2026 Canada Nanopharmaceutical Drugs Market, 2017- 2026 59 Europe Nanopharmaceutical Drugs Market, 2017- 2026 Europe Market Dynamics Europe Nanopharmaceutical Drugs Market (by Country), 2017-2026 Germany Nanopharmaceutical Drugs Market, 2017-2026 France Nanopharmaceutical Drugs Market, 2017- 2026 The U.K. Nanopharmaceutical Drugs Market, 2017-2026 Spain Nanopharmaceutical Drugs Market, 2017- 2026 Italy Nanopharmaceutical Drugs Market, 2017- 2026 Rest-of-Europe Nanopharmaceutical Drugs Market, 2017-2026 Asia-Pacific Nanopharmaceutical Drugs Market, 2017-2026 Asia-Pacific Market Dynamics Asia Pacific Nanopharmaceutical Drugs Market (by Country), 2017-2026 China Nanopharmaceutical Drugs Market, 2017- 2026 Japan Nanopharmaceutical Drugs Market, 2017- 2026 Rest-of-Asia Pacific Nanopharmaceutical Drugs Market, 2017-2026 Rest-of-the-World Nanopharmaceutical Drugs Market, (by Drug Carrier), 2017-2026 Rest-of-the-World Nanopharmaceutical Drugs Market, (by Application), 2017-2026 Abbvie Inc.: Product Offerings for Global Nanopharmaceutical Drugs Market Abbvie Inc.: Overall Financials, 2015-2017 Abbvie Inc.: Revenue (by Region), 2015, 2016 and 2017 Abbvie Inc.: R&D Expense, 2015-2017 Abbvie Inc.: Revenue Forecast, 2015-2020 Abbvie Inc.: Global Presence Abbvie Inc.: SWOT Analysis AMAG Pharmaceuticals: Product Offerings for Global Nanopharmaceutical Drugs Market AMAG Pharmaceuticals: Overall Financials, 2015- 2017 AMAG Pharmaceuticals: Revenue (by Business Segment), 2015-2017 AMAG Pharmaceuticals: R&D Expense, 2015-2017 AMAG Pharmaceuticals: Revenue Forecast, 2015- 2020 34 60 61 35 62 36 63 37 64 38 65 39 66 40 67 41 42 68 43 69 70 44 71 45 72 46 73 47 74 48 75 49 76 50 77 78 51 79 80 81 82 83 52 53 54 55 56 84 85 57 86 87 58 14 www.bisresearch.com  sales@bisresearch.com

5. LIST OF FIGURES 88 89 90 AMAG Pharmaceuticals: Global Presence AMAG Pharmaceuticals: SWOT Analysis Amgen, Inc.: Product Offerings for Global Nanopharmaceutical Drugs Market Abbvie Inc.: Overall Financials, 2015-2017 Amgen Inc.: Revenue (by Region), 2015, 2016 and 2017 Amgen, Inc.: R&D Expense, 2015-2017 Amgen, Inc.: Revenue Forecast, 2015-2020 Amgen Inc.: Global Presence Amgen, Inc.: SWOT Analysis Astellas Pharma Inc.: Product Offerings for Global Nanopharmaceutical Drugs Market Astellas Pharma Inc: Overall Financials, 2015- 2017 Astellas Pharma Inc: Revenue (by Business Segment), 2016-2017 100 Astellas Pharma Inc.: Revenue (by Region), 2016-2017 101 Astellas Pharma Inc: R&D Expense, 2015-2017 102 AstraZeneca PLC: Revenue Forecast, 2015-2020 103 Astella Pharma Inc, SWOT Analysis 104 AstraZeneca PLC: Overall Financials, 2015-2017 105 AstraZeneca PLC: Revenue (by Region), 2015- 2017 106 AstraZeneca PLC: R&D Expense, 2015-2017 107 AstraZeneca PLC: Global Presence 108 AstraZeneca PLC: SWOT Analysis 109 CELGENE CORPORATION: Product Offerings for Global Nanopharmaceutical Drugs Market 110 CELGENE CORPORATION: Overall Financials, 2015-2017 111 CELGENE CORPORATION: Revenue (by Region), 2015-2017 112 CELGENE CORPORATION: R&D Expense, 2015- 2017 113 CELGENE CORPORATION: Revenue Forecast, 2015-2020 114 CELGENE CORPORATION: Global Presence 115 CELGENE CORPORATION: SWOT Analysis 116 Sciences, Inc: Product Offerings for Global Nanopharmaceutical Drugs Market 117 Gilead Sciences, Inc: Overall Financials, 2015- 2017 118 Gilead Sciences, Inc: Revenue (by Region), 2015- 2017 119 Gilead Sciences, Inc: R&D Expense, 2015-2017 120 Gilead Sciences, Inc: Revenue Forecast, 2015- 2020 121 Gilead Sciences, Inc: Global Presence 122 Gilead Sciences, Inc: SWOT Analysis 123 Johnson & Johnson: Product Offerings for Global Nanopharmaceutical Drugs Market 124 Johnson & Johnson: Overall Financials, 2015- 2017 125 Johnson & Johnson: Revenue (by Business Segment), 2015-2017 126 Johnson & Johnson: Revenue (by Region), 2015- 2017 127 Johnson & Johnson: R&D Expense, 2015-2017 128 Johnson & Johnson: Revenue Forecast, 2015- 2020 129 Johnson & Johnson: Global Presence 130 Johnson & Johnson: SWOT Analysis 131 Merck & Co., Inc.: Product Offerings for Global Nanopharmaceutical Drugs Market 132 Merck & Co., Inc.: Overall Financials, 2015-2017 133 Merck & Co., Inc.: Revenue (by Business Segment), 2015-2017 134 Merck & Co., Inc.: Revenue (by Region), 2015- 2017 135 Merck & Co., Inc.: R&D Expense, 2015-2017 136 Merck & Co., Inc.: Revenue Forecast, 2015-2020 137 Merck & Co., Inc.: Global Presence 138 Merck & Co., Inc.: SWOT Analysis 139 Novartis AG: Product Offerings for Global Nanopharmaceutical Drugs Market 140 Novartis AG: Overall Financials, 2015-2017 141 Novartis AG: Revenue (by Business Segment), 2015-2017 142 Novartis AG: Revenue (by Region), 2015-2017 143 Novartis AG: R&D Expense, 2015-2017 144 Novartis AG: Revenue Forecast, 2015-2020 145 Novartis AG: Global Presence 146 Novartis AG: SWOT Analysis 147 Pfizer, Inc.: Product Offerings for Global Nanopharmaceutical Drugs Market 148 Pfizer, Inc.: Overall Financials, 2015-2017 149 Pfizer, Inc.: Revenue (by Business Segment), 2015, 2016 and 2017 150 Pfizer, Inc.: Revenue (by Region), 2015, 2016 and 2017 151 Pfizer, Inc.: R&D Expense, 2015-2017 152 Pfizer, Inc.: Revenue Forecast, 2015-2020 91 92 93 94 95 96 97 98 99 15 www.bisresearch.com  sales@bisresearch.com

6. LIST OF FIGURES 153 Pfizer, Inc.: Global Presence 154 Pfizer, Inc.: SWOT Analysis 155 F. Hoffmann-La Roche AG: Product Offerings for Global Nanopharmaceutical Drugs Market 156 F. Hoffmann-La Roche AG: Overall Financials, 2015-2017 157 F. Hoffmann-La Roche AG: Revenue (by Business Segment), 2015-2017 158 F. Hoffmann-La Roche AG: Revenue (by Region), 2015-2017 159 F. Hoffmann-La Roche AG: R&D Expense, 2015- 2017 160 F. Hoffmann-La Roche AG: Revenue Forecast, 2015-2020 161 F. Hoffmann-La Roche AG: Global Presence 162 F. Hoffmann-La Roche AG: SWOT Analysis 163 Sanofi S.A.: Product Offerings for Global Nanopharmaceutical Drugs Market 164 Sanofi S.A: Overall Financials, 2015-2017 165 Sanofi S.A: Revenue (by Business Segment), 2015-2017 166 Sanofi S.A: Revenue (by Region), 2015-2017 167 Sanofi S.A: R&D Expense, 2015-2017 168 Sanofi S.A: Revenue Forecast, 2015-2020 169 Sanofi S.A: Global Presence 170 Sanofi S.A: SWOT Analysis 171 Shire plc.: Product Offerings for Global Nanopharmaceutical Drugs Market 172 Shire plc.: Overall Financials, 2015-2017 173 Shire PLC: Revenue (by Business Segment), 2015-2017 174 Shire PLC: R&D Expense, 2015-2017 175 Shire PLC: Revenue Forecast, 2015-2020 176 Shire PLC: Global Presence 177 Shire PLC: SWOT Analysis 178 Teva Pharmaceuticals Industries Limited: Product Offerings for Global Nanopharmaceutical Drugs Market 179 Teva Pharmaceuticals Industries Limited: Overall Financials, 2015-2017 180 Teva Pharmaceuticals Industries Limited: Revenue (by Business Segment), 2015-2017 181 Teva Pharmaceuticals Industries Limited: Revenue (by Region), 2015-2017 182 Teva Pharmaceuticals Industries Limited: R&D Expense, 2015-2017 183 Teva Pharmaceuticals Industries Limited: Revenue Forecast, 2015-2020 184 Teva Pharmaceuticals Industries Limited: Global Presence 185 Teva Pharmaceuticals Industries Limited: SWOT Analysis 186 Global Nanopharmaceutical Drugs Market Scope 187 Global Nanopharmaceutical Drugs Market: Research Methodology 188 Primary Research 189 Secondary Research 190 Data Triangulation 191 Top-down Approach (Segment-wise Analysis) 192 Bottom-up Approach (Segment-wise Analysis) 193 Assumptions and Limitations 194 Considered Factors for Data Prediction and Modelling 16 www.bisresearch.com  sales@bisresearch.com

7. 1 Research Scope & BIS Methodology 1.1 Scope of the Report The report constitutes of an in-depth study of the global nanopharmaceutical market , including a thorough analysis of the types of nanocarriers such as liposomes, polymer, nanocrystal, inorganic, proteins and others used to facilitate drug delivery. The nanopharmaceutical market is also studied based on different applications such as oncology, neurology, anti-inflammatory/immunology, anti-infectives, cardiovascular and other therapeutic areas. The study also incorporated the nanopharmaceutical market analysis based on distribution channel and region. The study also presents a detailed analysis of the market dynamics and the estimation of the market size over the forecast period 2018-2026. Nanomedicine has a multidisciplinary nature involving notions and techniques from biology, chemistry, and physics. Nanotechnology provides exceptional benefits when applied to medical devices and pharmaceuticals. The main application of nanotechnology in the medical sector is in the field of drug delivery. The methods for the synthesis, function, and use of nanoparticles and nanocarriers have flooded the scientific and clinic community with therapeutic applications from molecular targeting to radiofrequency ablation, personalized therapies and minimally invasive techniques. In the report, the cost of nanopharmaceutical drug has been considered. The market value may vary from 5.00-7.00% as the data has been collected from different sources at the regional and country level. The market analysis includes an in-depth examination of the key ecosystem players and key strategies and developments taking place in this market. Additionally, it includes the market dynamics (market drivers, opportunities, and challenges) and industry analysis. The purpose of the study is to gain a holistic view of the global nanopharmaceutical market in terms of various factors influencing the market, including regulatory reforms, drug clinical outcome and pipeline opportunity, and technological advancements. The market has been segmented into ‘drug carrier type, ‘application’, ‘distribution channel’, and ‘regions’. The scope of this report is centred upon conducting a detailed study of the drugs allied with the nanopharmaceutical market. No real-time data was available in the public domain, personnel from the respective companies were contacted in order to gain valuable information pertaining to the test in different regions and their corresponding price. This information was then used to estimate the global number of different nanopharmaceutical drugs, which was later validated by the industry experts. Figure 1 BIS Research Market Research Methodology RESEARCH APPROACH PRIMARY RESEARCH SECONDARY RESEARCH 1. DATABASE FOR KEY INDUSTRY PARTICIPANTS (DKIP) PREPARATION STUDYING THE MARKET STRUCTURE The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing directors, technology and innovation directors, and related key executives from various vendors providing technology solutions, associated service providers, and system integrators operatingin the targetedregions. E.g. CIO’s, VP, DirectorNew ProductDevelopment,Director–operations Mainly used to obtain key information about the industry’s value chain, the total pool of key players IDENTIFY MARKET, TECHNOLOGY AND COMPETITOR TRENDS 2. DISCUSSION GUIDE PREPARATION Understand market classification, and segmentation according to industry trends to the bottom-most level, regional markets, and key developments from both market- and technology-oriented perspectives A detailed questionnaire is shared with the primary respondent covering all the aspects related to the report topic 3. SCHEDULING AN APPOINTMENT Appointments are scheduled with CIO’s, VP – healthcare companies, Director with prior appointmentsand the discussionguide is shared with the primary respondentprior to the call INTEGRATE INFORMATION Integrate information within relevant documents to form launch pad for primary research 4. CALL EXECUTION A roundtable discussion is held with the KIP with the aim to gather first hand information about the technology,recent developmentsin the technologyand future outlook/ growthor decline VENDORS CONSULTANT RESELLERS 5. DOCUMENTATION POTENTIAL RESPONDENTS The interview is recorded and the information gathered in put on the drawing board with the informationcollectedthroughsecondary research. END USER MSP’s BIS Research Analysis 23 www.bisresearch.com  sales@bisresearch.com

8. Primary Data Sources The key data points taken from Primary Sources includes: • Validation and Triangulation of all the numbers and graphs • Validation of report segmentation and key qualitative findings • Understanding the competitive landscape • Understanding and considering the market dynamics factors for various market segment and sub- segment • Validation of impact analysis of macro and micro factors in different countries • Percentage split of individual markets for geographical analysis Secondary Data Sources The research study involves the usage of extensive secondary sources such as databases, company websites, and annual reports, among others. The following figure exhibits key secondary data sources considered in this report: Figure 2 Secondary Data Sources STOCK ANALYST WEBSITES COMPANY SOURCES Seeking Alpha Yahoo Finance Wiki Finance The Wall Street Journal Annual Reports Press Releases SEC Filings Investor Presentations Financial Disclosures SECONDARY DATA SOURCES GOVERNMENT, NON-GOVERNMENT AND REGULATORY SOURCES The World Health Organization (WHO) The National Center for Biotechnology Information (NCBI) The Food & Drug Administration of United States (U.S. FDA) National Nanotechnology Initiative (NNI) European Centre for Nanomedicine PUBLIC AND PRIVATE DATABASES Medline PubMed National Library of Medicine ProQuest Thin Database CMS Datasets Medicare Beneficiaries Database Oxon Epidemiology Pharmaceutical & Biotechnology Research Databases (EBSCO) BIS Research Analysis 24 www.bisresearch.com  sales@bisresearch.com

9. The key data points taken from secondary sources include: • Segmentation breakups, split-ups, and percentage shares • Data for market value • Key industry trends of the top players of the market • Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation • Quantitative data for mathematical and statistical calculations The following figure exhibits data triangulation considered in this study: Figure 3 Data Triangulation PRIMARY SOURCES SECONDARY SOURCES INTERVIEWS WITH: • Top management of leading companies manufacturing nanopharmaceuticals • Academic and Government Research Institutes initiating research on nanotechnology and nanomedicine • C-level executives of start-up companies innovating in the field of nanotechnology • Scientists and researchers from renowned universities working in the field of drug carriers, nanotechnology and nanomedicine approach • Annual reports from the leading players in the nanopharmaceutical drugs market INFORMATION SOURCED • National Centre of Biotechnology Information SUPPLY SIDE • The World Bank DATA TRIANGULATION PRIMARY SOURCE SECONDARY SOURCE Annual Reports, SEC Filings, Investor Presentations, Websites, and Press Releases of top players, News Articles, Journals, and Paid Databases INFORMATION SOURCED Opportunities/ Challenges Market Size and Market Share Key Players Competitive Landscape Geographical Analysis Influencing Factors Market Estimates Market Trends BIS Research Analysis REQUEST FOR SAMPLE 25 www.bisresearch.com  sales@bisresearch.com